Catalase application in cancer therapy: Simultaneous focusing on hypoxia attenuation and macrophage reprogramming - 31/08/22
, Mehdi Khoobi c, e, ⁎ 
Abstract |
The tumor microenvironment (TME), as an immunosuppressive milieu, has a critical role in tumor progression and increases resistance to the conventional treatments. Among the abundant immunosuppressive cells in the TME, tumor-associated macrophages (TAMs) could be a promising target for reprogramming and potentiating the local anti-tumor response. On the other hand, hypoxia is a major barrier in treating solid tumors, which aggravates the situation and alleviates the anti-tumor immune responses. Moreover, catalase and catalase-mimicking compounds can efficiently participate in the TAMs polarization and hypoxia attenuation in the TME. In this review, we will introduce a practical and novel approach which can simultaneously reduce hypoxia and polarize TAMs in the TME. Furthermore, catalase therapeutic effects in combination with cancer therapy methods will be fully discussed. This work aims to inspire readers to explore new avenues for designing and development of next-generation catalase-based formulations for cancer therapy.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Hypoxia and infiltrated TAMs are the major challenges in cancer immunotherapy and manipulating the TME. |
• | The produced H 2 O 2 in the TME can be degraded by catalase and generate O 2 , leading to hypoxia attenuation. |
• | Catalase can simultaneously attenuate hypoxia, polarize TAMs towards an anti-tumoral phenotype, and open a new cancer treatment landscape. |
• | Components that mimic catalase activity provide a novel strategy to overcome catalase strategy limitations. |
Keywords : Catalase, Hypoxia, Macrophage polarization, Nanozyme, Tumor-associated macrophage, Tumor microenvironment
Plan
Vol 153
Article 113483- septembre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
